Wisconsin hospitals filed 37% more lawsuits against patients from 2001 to 2018, study finds
Fierce Healthcare
DECEMBER 7, 2021
Wisconsin hospitals filed 37% more lawsuits against patients from 2001 to 2018, study finds. Tue, 12/07/2021 - 12:07.
2001 Related Topics 
Officials Release Draft Legislation Aimed at Prescription Drug Shortage Issues
Pharmacy Times
MAY 8, 2024
Ongoing and active shortages are currently at the highest number since January 2001.
131 Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Regulatory-first for gene editing therapy
European Pharmaceutical Review
OCTOBER 19, 2023
The Investigational New Drug (IND) application for Intellia Therapeutics’ in vivo CRISPR-based candidate NTLA-2001, has been cleared as a gene editing therapy for transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) in the US. This supports NTLA-2001’s potential as a single-administration therapeutic.
FDA 105
105 FDA 105
105 
Number of ongoing US drug shortages reaches new high, pharmacist group says
Fierce Pharma
APRIL 11, 2024
as of 2024’s first quarter—the highest number recorded since ASHP began tracking shortage data back in 2001. . | The American Society of Health-System Pharmacists has released new data showing there were 323 drugs in shortage in the U.S.
119 
5 takeaways from the Human Genome Project investigation
STAT
JULY 9, 2024
But that’s not how it turned out: One individual’s DNA accounted for the vast majority of the genome when a first draft was released in 2001. Read the rest…
124 
Opinion: Stigma and the return of syphilis
STAT
MAY 30, 2024
at epidemic rates that have been climbing since 2001. Syphilis, one of the oldest infections known to humans, has returned to the U.S. In 2022, the last year with complete data, the highest number of infections were recorded in more than 70 years.
144 
STAT+: Drug shortages reached a record high as 2023 drew to a close
STAT
APRIL 10, 2024
stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country. The number of ongoing and active drug shortages in the U.S.
Chemotherapy 138
138 
STAT+: For one rare type of lung cancer, Pfizer pill reduces progression by 81%
STAT
MAY 31, 2024
The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal.
145 
STAT+: Gilead to pay $40 million to settle claims it delayed newer HIV treatment to boost profits
STAT
JUNE 5, 2024
” Here is the back story: In 2001, Gilead won U.S. For its part, the company issued a statement in which it did not admit wrongdoing and continued to maintain it has “never stopped working to improve the lives of people with HIV.”
145 
STAT+: Departing Stanford president retracts two widely cited papers, against lead author’s wishes
STAT
AUGUST 31, 2023
The retractions come the same day that Tessier-Lavigne’s resignation as Stanford president takes effect.
139 
Opinion: I grew up in one of Africa’s largest informal settlements. Now I’m helping heal it
STAT
NOVEMBER 24, 2023
In 2001, at the age of 13, I had come to Kenya’s largest informal settlement on the outskirts of Nairobi with my sister. I had only lived in Kibera for 15 minutes when I saw a police officer and was arrested. But it would be years before I saw a real doctor. When we arrived at 3 a.m.,
117 
Mistakes happen in research papers. But corrections often don’t
STAT
JANUARY 10, 2023
Five studies co-authored by Tessier-Lavigne are now under the microscope for containing alleged altered images: a 1999 Cell study , a 2008 paper in the EMBO Journal, a 2003 Nature study, and two studies published in 2001 in Science.
128 
Opinion: STAT+: 3 keys to successful biopharma-academia drug development collaborations
STAT
MARCH 31, 2023
Indeed, academic inventors or founders contributed to more than one-quarter of all medicines approved from 2001 through 2019. Academia can be an excellent source of novel drug targets and new technologies that can enhance medicinal discovery. Yet many sponsored research collaborations that hope to tap into academia fail.
105 
REGiMMUNE Entered into a License Agreement with San Fu Biotech to Develop and Commercialize RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease
PharmaShots
APRIL 3, 2023
REGiMMUNE’s RGI-2001 is currently in P-III trial for the prophylaxis of aGVHD Ref: Businesswire | Image: Regimmune Related News:- Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular Carcinoma
40 
Suicides and homicides among young Americans jumped early in the pandemic, study says
STAT
JUNE 15, 2023
The Centers for Disease Control and Prevention report examined the homicide and suicide rates among 10- to 24-year-olds from 2001 to 2021. The homicide rate for older U.S. Read the rest…
98 
Shorla gains FDA nod for first oral liquid version of Novartis' Gleevec
Fierce Pharma
NOVEMBER 26, 2024
In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “am | Shorla Oncology has scored an FDA approval for its strawberry-flavored drink version of Novartis' cancer drug Gleevec. Dubbed Imkeldi, it becomes the first oral liquid form of imatinib.
FDA 84
84 FDA 84
84 
STAT+: Amgen’s $27.8 billion Horizon merger is latest industry bet on pricey rare disease drugs
STAT
DECEMBER 12, 2022
The deal is the largest pharma merger announced this year, and it represents the most that Amgen has spent on an acquisition since its $16 billion purchase of Immunex in 2001. Amgen said Monday it would purchase Horizon Pharmaceuticals for $27.8 Continue to STAT+ to read the full story…
Opinion: STAT+: A California court is setting a dangerous precedent over drug development (or lack thereof) liability
STAT
FEBRUARY 13, 2024
In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage.
FDA 114
114 FDA 114
114 
Half of people worldwide at risk of developing mental health condition by age 75, per new study
STAT
AUGUST 8, 2023
The study, published last week in The Lancet Psychiatry , analyzed answers that participants provided between 2001 and 2022 in response to a World Health Organization survey designed to assess the prevalence of major mental health disorders.
98 
STAT+: Medicare may test policy of paying less for accelerated approval drugs
STAT
JANUARY 31, 2023
The program is widely considered a success and has worked well for many drugs, including the leukemia drug Gleevec , which the FDA approved in 2001 after a review period of just two-and-a-half months, based on study results that correctly predicted successful clinical outcomes. Continue to STAT+ to read the full story…
FDA 98
98 FDA 98
98 
Women in Science: Trinity Life Sciences’ Leslie Orne: ‘I love the energy and dynamism of consulting’
Outsourcing Pharma
JULY 26, 2023
Leslie Orne joined Trinity Life Sciences in 2001 and was recently appointed CEO and president of the fast-growing healthcare consultancy. She previously held the title of chief commercial officer (CCO) and president.
78 
Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drug
pharmaphorum
JUNE 28, 2021
Preliminary results from a phase 1 trial run by Regeneron and CRISPR specialist Intellia Therapeutics – co-founded by Nobel Prize winner Jennifer Doudna – showed steep reductions in a biomarker of ATTR amyloidosis disease activity with a single dose of the NTLA-2001 drug.
Packaging 105
105 Packaging 105
105 
Heart failure: clinical trials update 2022
European Pharmaceutical Review
NOVEMBER 11, 2022
NTLA-2001, a novel CRISPR/Cas9-based therapy in the first-ever human gene editing trial ( NCT04601051 ) in vivo (in the body), reduced transthyretin (TTR) proteins by at least 90 percent in amyloidogenic transthyretin (ATTR) cardiomyopathy patients, 28 days after a single IV infusion, with benefits lasting four to six months.
Labelling 119
119 
How telehealth startups are trying to fill the menopause care vacuum
STAT
JULY 17, 2023
The study was shut down early — and a year later, prescriptions had plummeted to nearly half what they had been in 2001. But in 2002, the therapy went into a free-fall when a landmark trial suggested treating menopause with estrogen and progesterone increased the risk of breast cancer and cardiovascular disease.
98 
STAT+: Pharmalittle: Amgen agrees to pay $27.8 billion for Horizon Therapeutics; Roche pharma head steps down
STAT
DECEMBER 12, 2022
The deal is the largest pharmaceutical merger announced this year, and it represents the most that Amgen has spent on an acquisition since its $16 billion purchase of Immunex in 2001. The The product is expected to generate $1.97 billion in 2022 and $2.26 billion in 2023, according to FactSet, an investment data firm.
98 
Lilly looks inward as it completes hunt for new CFO with appointment of 23-year vet Lucas Montarce
Fierce Pharma
SEPTEMBER 9, 2024
Montarce, who’s been with the Indianapolis-based drugmaker since 2001, most recently worked as Lilly's president and general manager for the company’s hub in Spain, Portugal and Greece.
63 
Intellia’s gene editing therapy shows early potential in rare heart condition
Pharmaceutical Technology
NOVEMBER 18, 2024
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in Chicago.
52 
STAT+: Pharmalittle: We’re reading about drug shortages, Medicare spending on an Alzheimer’s drug, and more
STAT
APRIL 11, 2024
stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country, STAT tells us. Unresolved The number of ongoing and active drug shortages in the U.S.
Chemotherapy 103
103 
FDA grants orphan drug status for Ichnos’ multiple myeloma antibody
Pharmaceutical Technology
JULY 10, 2023
The US FDA has granted orphan drug designation (ODD) for Ichnos Sciences’ ISB 2001 to treat patients with multiple myeloma.
FDA 52
52 FDA 52
52 
Huge inequalities found in access to myeloma clinical trials in Europe, says MPE
pharmaphorum
DECEMBER 1, 2022
Led by the MPE CEE Workgroup on Access, the report – Addressing access barriers to myeloma clinical trials in Central and Eastern Europe – evaluated the number of clinical trials held in CEE countries between 1 January 2001 and 28 September 2020. Approximately 50,000 people in Europe are diagnosed with myeloma each year.
72 
Minneceutics Newsletter
Blog: Ask a Student Pharmacist
OCTOBER 4, 2023
Minneceutics Newsletter eomizowh Wed, 10/04/2023 - 12:47 Current Newsletter Expand all + Archive 1993 1994 1995 1999 2000 2001 2002 2003 2004 2006 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
52 
2022 spells change for EU pharmaceutical legislation
European Pharmaceutical Review
JUNE 24, 2022
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. One of the key priorities of the EU’s strategy is to encourage innovation to solve unmet medical needs. Brussels; 2020.
Compounding 106
106 
Nuclear Pharmacist by Day, DJ by Night
Pharmacy Is Right For Me
OCTOBER 21, 2022
I worked in Dallas from 95-2001, then moved to NYC, then years later went to the University of Colorado for the NTPD program and received the PharmD. What makes your career path unique? My focus in Pharmacy School at OU was Nuclear Medicine. There was a fully operational Nuclear Pharmacy on campus, and I took all the courses.
Hospitals 130
130 
Psychedelic medicines: are they gaining traction in Europe?
European Pharmaceutical Review
APRIL 13, 2023
For example, the relaxed attitude towards cannabis in the Netherlands is well-known and Portugal has decriminalised the possession and consumption of all illicit substances since 2001.
Envision acquires commercial solutions firm Two Labs
pharmaphorum
NOVEMBER 18, 2020
Since being founded in 2001, Envision has delivered strong year-on-year organic growth and established leadership in medical affairs strategy, medical communications, and enterprise-wide Envision technology.
Prescribing Red Flags, Corresponding Responsibility and DEA Investigations: What’s a Pharmacist To Do?
The FDA Law Blog
FEBRUARY 19, 2023
Mr. Houck was a diversion investigator with the Drug Enforcement Administration (“DEA”) in the field and at agency headquarters for 15 years before joining HPM in 2001. at this year’s American Pharmacists Association’s (“APhA’s”) Annual Meeting in Phoenix, March 24-27.
Ibuprofen for chickenpox – can you use it? [ANSWERED]
Druggist
NOVEMBER 13, 2020
2001) was similar to the previously discussed research. 2001 May;107(5):1108-15. Additionally, it was suggested more research is needed to check the role of ibuprofen in getting NF. Study 2 – do NSAIDs increase the risk of infections in children with chickenpox . The objective of this study (Lesko et al., Pediatrics. doi: 10.1542/peds.107.5.1108.
Hospitals 98
98 Hospitals 98
98 
New CEO Mortazavi takes UK biotech e-therapeutics into gene silencing
pharmaphorum
OCTOBER 13, 2020
Since it was founded in 2001 the company has become one of the country’s best known biotechs thanks to its approach to designing drugs based around network biology.
100 
Bridging the healthcare digital divide: a gradual approach to adopting ePI
European Pharmaceutical Review
JANUARY 25, 2024
Proposal for a Directive of the European Parliament and of the Council on the Union code relating to medicinal products for human use, and repealing Directive 2001/83/EC and Directive 2009/35/EC.” References European Commission, (26 April 2023). Article 63 EMA (29 January 2020). Article 63 Euractiv (26 September 2023).
Packaging 98
98 
ExeVir ready for clinic with variant-targeting llama antibody
pharmaphorum
MARCH 9, 2021
billion acquisition at the end of 2018, span out of VIB in 2001 and developed drugs based on similar technology. ExeVir is not the first company to spin out of VIB to focus on camelid antibodies. Ablynx, which is now a subsidiary of Sanofi following a $4.8
Immunization 98
98 
Peculiar Articles: 10 Potential Conversation Starters From The Medical Literature
IDStewardship
DECEMBER 15, 2024
– On the risks of cannabisuse. Effects of remote, retroactive intercessory prayer on outcomes in patients with bloodstream infection: randomised controlled trial. – On positive vibes, patient outcomes, and study designs. Association Between Patient Perception of Surgeons and Color of Scrub Attire. JAMA Surgery.
130 
Roivant joins RNA splicing push with Eisai deal
pharmaphorum
JANUARY 6, 2022
H3B-8800 – now renamed RVT-2001 – will be taken in a slightly different direction by Roivant, which said it plans to develop it as a therapy for transfusion-dependent anaemia in patients with lower-risk MDS, according to the company.
Compounding 52
52 Compounding 52
52 
College of Pharmacy Golf Classic
Blog: Ask a Student Pharmacist
JANUARY 9, 2024
College of Pharmacy Golf Classic eomizowh Tue, 01/09/2024 - 10:12 9:00am 5:00pm Midland Hills Country Club 2001 Fulham St Roseville MN 55113 Header Alignment Left Event Type In-Person This event is no longer available. View all of the Site Name Here events by visiting our Events page [link to events.umn.edu or events page on this website].
40 
Botanical drugs – what is the best way forward for regulatory and market approval?
European Pharmaceutical Review
JULY 4, 2024
11 The THR pathway was created with the purpose of establishing a simplified registration procedure for all traditional herbal medicines that do not fulfil the requirements for the MA (strict) pathway under Directive 2001/83/EC. 10,12 The THR scheme is also limited to products used for oral or external use and/or inhalation. 2012/1916).
FDA 104
104 
Let's personalize your content